ABVX stock forecast, quote, news & analysis
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases... Show more
ABIVAX Société Anonyme (ABVX) Full Year 2025 Earnings Recap: Surging R&D Fuels Clinical Push
Key Takeaways
- ABIVAX Société Anonyme reported full year 2025 total operating income of €4.6 million, down from €12.4 million in 2024.
- Net loss widened to €336.1 million from €176.2 million in 2024, driven by higher R&D expenses of €177.8 million and G&A of €67.7 million.
- Cash position strengthened to €530.4 million as of December 31, 2025, providing runway into Q4 2027 after €597.2 million raised via public offering.
- Operating loss increased to €246.1 million, reflecting accelerated investment in obefazimod Phase 3 trials for ulcerative colitis.
- ABTECT Phase 3 maintenance trial on track for topline data in late Q2 2026; positive DSMB review in March 2026.
- All debt tranches settled, bolstering balance sheet ahead of key 2026 milestones.
Earnings Context and Why It Matters
As a clinical-stage biotech targeting immune modulation for chronic inflammatory diseases, ABIVAX Société Anonyme's full year 2025 results highlight its pivot toward late-stage development of lead candidate obefazimod. The widened net loss underscores heavy R&D investment amid Phase 3 ABTECT trials in ulcerative colitis, where positive data could unlock regulatory submission and commercialization. With ulcerative colitis affecting millions and limited oral therapies available, investors eye these results for signals on trial progress, cash burn, and funding sustainability. Recent €597 million capital raise extended runway, but rising expenses amid biotech sector pressures make fiscal discipline critical for bridging to potential 2026 NDA filing.
Earnings Expectations or Reported Results
ABIVAX Société Anonyme released its full year 2025 financials on March 23, 2026, covering the period ended December 31, 2025. Total operating income fell to €4.6 million from €12.4 million in 2024, mainly from lower research tax credits and subsidies. Operating expenses rose sharply, with R&D at €177.8 million (up €31.2 million year-over-year, 96.5% tied to obefazimod) and G&A at €67.7 million (up €34.7 million due to personnel costs). This drove operating loss to €246.1 million (vs. €173.0 million) and net loss before tax to €330.3 million (vs. €176.2 million), with net loss at €336.1 million after €5.8 million tax.
Cash flows from operations used €161.1 million (vs. €154.1 million), offset by €372.5 million net cash increase from financing, including the July 2025 ADS offering. Balance sheet shows €530.4 million in cash, equivalents, and short-term investments, up significantly post-raise and debt settlements.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, selected from hundreds that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots employ varied approaches—from momentum and mean reversion to pattern recognition and sentiment analysis—delivering audited stats like annualized returns up to 150%+, win rates exceeding 70% in some cases, and Sharpe ratios above 2.0. Only those demonstrating robust risk-adjusted performance and adaptability to volatility earn a spot in this curated section, helping traders identify tools suited for current environments like biotech swings. Explore these high-conviction options to enhance your trading edge.
Market Reaction and Investor Sentiment
ABVX shares closed down 4.09% at $115.42 on March 23, 2026, following the earnings release, with after-hours trading showing modest rebound to $117.00. The decline reflects investor digestion of the doubled net loss amid elevated R&D spend, despite strong cash position and clean debt sheet. Sentiment remains cautiously optimistic, buoyed by Phase 3 progress and Q4 2027 runway, though focus sharpens on ABTECT topline data. Jefferies' recent Buy rating with $160 target underscores trial momentum, but biotech peers' volatility tempers enthusiasm ahead of catalysts.
Forward Outlook and Key Factors to Monitor
Following full year 2025 results, ABIVAX Société Anonyme enters 2026 with €530.4 million cash supporting operations into Q4 2027 under current plans. Investors should track ABTECT Phase 3 maintenance trial topline results expected late Q2 2026, pivotal for obefazimod's ulcerative colitis NDA filing targeted Q4 2026 if positive. Phase 2b induction trial in Crohn's disease advances toward Q4 2026 completion, with DSMB's recent no-safety-signal endorsement adding confidence.
New leadership in commercial, regulatory, and research roles positions the company for potential launch, while settled debts reduce dilution risks. Upcoming Q1 2026 results on May 25 and AGM on May 11 offer further visibility. Broader monitors include R&D burn rate amid trial wind-downs, grant income fluctuations, and industry dynamics like UC market growth and competitor readouts. Margin pressures from staffing persist, but fundraising success signals access to capital. Positive data could catalyze partnerships; delays or safety issues pose headwinds in a competitive immunology space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ABVX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on March 27, 2026
ABVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 12 cases where ABVX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABVX's RSI Indicator exited the oversold zone, of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 07, 2026. You may want to consider a long position or call options on ABVX as a result. In of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABVX just turned positive on April 02, 2026. Looking at past instances where ABVX's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
ABVX moved above its 50-day moving average on April 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABVX crossed bullishly above the 50-day moving average on April 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVX advanced for three days, in of 161 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 27 cases where ABVX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ABVX entered a downward trend on April 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.730) is normal, around the industry mean (26.681). P/E Ratio (0.000) is within average values for comparable stocks, (45.953). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (192.308) is also within normal values, averaging (325.679).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology